Nah I know phase 2 will show potential to move to phase 3 NA-1 has the same results. Safety studies will also be positive as per NA-1. It’s the same drug class and multiple peptides have passed these points and all have failed in this drug class because these peptides couldn’t even show 1 percent efficacy. Having a long acting peptide in the same class won’t make a difference. It’s why the CEO in every recent interview states:
”We are looking at safety data, efficacy we just need to show any improvement” she’s hoping it’s not a NA-1 but the development of AGN all happened before these peptides all failed
AGN Media thread, page-247
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 80.0¢ | 78.0¢ | $12.31K | 15.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2093 | 79.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 14798 | 3 |
View Market Depth
| Last trade - 15.48pm 30/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |